|
Administration
May be taken with or without food.
|
|
Special Precautions
Patient with cardiac risks (e.g. long QT syndrome, hypokalaemia, treatment with agents known to increase QT interval). Concomitant use with CYP3A4 inhibitors. Severe hepatic impairment. Children. Pregnancy and lactation. Patient Counselling This drug may cause drowsiness or sometimes dizziness; if affected, do not drive or operate machinery.
|
|
Adverse Reactions
Cardiac disorders: Rarely, palpitation, tachycardia.
Gastrointestinal disorders: Dry mouth. Rarely, dysgeusia, abdominal pain, nausea, dyspepsia, vomiting.
General disorders and administration site conditions: Asthenia.
Hepatobiliary disorders: Rarely, hepatitis, cholestasis.
Immune system disorders: Rarely, hypersensitivity reactions (e.g. angioedema, anaphylaxis).
Investigations: Rarely, abnormal LFTs.
Nervous system disorders: Headache, drowsiness. Rarely, dizziness, hypoesthesia.
Psychiatric disorders: Rarely, nervousness, insomnia.
Reproductive system and breast disorders: Rarely, menstrual disorders.
Respiratory, thoracic and mediastinal disorders: Pharyngitis, sinusitis, epistaxis.
|
|
Drug Interactions
Increased plasma levels and risk of QTc interval prolongation with ketoconazole, itraconazole and erythromycin. Plasma concentrations and antihistamine effects may be decreased by rifampicin.
|
|
CIMS Class
|
|
ATC Classification
R06AX22 - ebastine ; Belongs to the class of other antihistamines for systemic use.
|
Sign Out
